{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:07:00Z","timestamp":1791162420682,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001831","name":"Lynn Sage Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001831","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["DAMD17-00-1-0386"],"award-info":[{"award-number":["DAMD17-00-1-0386"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["P50 CA89018-03"],"award-info":[{"award-number":["P50 CA89018-03"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["T32 CA70085-06"],"award-info":[{"award-number":["T32 CA70085-06"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000142","name":"Avon Foundation for Women","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.mrfmmm.2005.02.028","type":"journal-article","created":{"date-parts":[[2005,8,4]],"date-time":"2005-08-04T15:54:58Z","timestamp":1123170898000},"page":"247-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":216,"title":["Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance"],"prefix":"10.1016","volume":"591","author":[{"given":"Joan S.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Craig","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mrfmmm.2005.02.028_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1018770218022","article-title":"Role of hormones in cancer initiation and progression","volume":"3","author":"Russo","year":"1998","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/10739680490266162","article-title":"Gender-specific regulation of cardiovascular function: estrogen as key player","volume":"11","author":"Huang","year":"2004","journal-title":"Microcirculation"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocrinol. Rev."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev.physiol.66.032802.154945","article-title":"Estrogens in the nervous system: mechanisms and nonreproductive functions","volume":"66","author":"Maggi","year":"2004","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","year":"2002","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2004.04.009","article-title":"Association between uterine serous carcinoma and breast cancer","volume":"94","author":"Gehrig","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib7","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","article-title":"for the WHI Investigators, Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausual women: the Women's Health Initiative randomized trial","volume":"289","author":"Chlebowski","year":"2003","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib8","first-page":"7","article-title":"Cancer statistics","volume":"50","author":"Greenlee","year":"2000","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib9","first-page":"246","article-title":"Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture","volume":"48","author":"Henderson","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","article-title":"On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases","volume":"2","author":"Beatson","year":"1896","journal-title":"Lancet"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0277-5379(88)90173-3","article-title":"The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer","volume":"24","author":"Key","year":"1988","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.epirev.a036102","article-title":"Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk","volume":"15","author":"Pike","year":"1993","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib13","first-page":"533","article-title":"Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk","volume":"5","author":"Dorgan","year":"1996","journal-title":"Cancer Epidemiol. Biomark Prev."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-0760(03)00390-X","article-title":"Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells","volume":"87","author":"Russo","year":"2003","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0960-0760(03)00377-7","article-title":"Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis","volume":"86","author":"Yue","year":"2003","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib16","first-page":"1858","article-title":"Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism","volume":"46","author":"Li","year":"1987","journal-title":"Fed. Proc."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib17","first-page":"2156","article-title":"Localization of estrogen-induced DNA adducts and cytochrome P-450 activity at the site of renal carcinogenesis in the hamster kidney","volume":"47","author":"Liehr","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib18","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0960-0760(03)00372-8","article-title":"Aromatase inhibitors as adjuvant therapies in patients with breast cancer","volume":"86","author":"Coombes","year":"2003","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib20","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/sj.bjc.6601632","article-title":"Fulvestrant and the sequential endocrine cascade for advanced breast cancer","volume":"90","author":"Johnston","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib21","first-page":"1332","article-title":"Prevention of chemical carcinogenesis by Vitamin A and its synthetic analogs (retinoids)","volume":"35","author":"Sporn","year":"1976","journal-title":"Fed. Proc."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib23","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1535-6108(04)00059-5","article-title":"Selective estrogen receptor modulation: concept and consequences in cancer","volume":"5","author":"Jordan","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib26","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib27","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/0277-5379(90)90125-D","article-title":"The antiestrogens and anti-tumor properties of prolonged tamoxifen therapy in C3H\/OUJ mice","volume":"26","author":"Jordan","year":"1990","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/jnci\/83.7.492","article-title":"Suppression of mouse mammary tumoigenesis by long-term tamoxifen therapy","volume":"83","author":"Jordan","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2964(80)90156-5","article-title":"Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model","volume":"16","author":"Jordan","year":"1980","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib30","first-page":"4020","article-title":"Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model","volume":"47","author":"Gottardis","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib31","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/carcin\/13.12.2197","article-title":"Genotoxic potential of tamoxifen and analogues in female Fischer F344\/n rats, DBA\/2 and C57BL\/6 mice and in human MCL-5 cells","volume":"13","author":"White","year":"1992","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/carcin\/22.6.839","article-title":"Understanding the genotoxicity of tamoxifen?","volume":"22","author":"Phillips","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/carcin\/14.2.315","article-title":"The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat","volume":"14","author":"Williams","year":"1993","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib34","first-page":"3919","article-title":"Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats","volume":"53","author":"Greaves","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib35","first-page":"1360","article-title":"Induction of covalent DNA adducts in rodents by tamoxifen","volume":"52","author":"Han","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib36","first-page":"66","article-title":"Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen","volume":"56","author":"Osborne","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib37","article-title":"Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity","volume":"24","author":"Tannenbaum","year":"1997","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/carcin\/15.4.589","article-title":"A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes","volume":"15","author":"Lim","year":"1994","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/carcin\/15.3.439","article-title":"A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism","volume":"15","author":"Potter","year":"1994","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib40","first-page":"1288","article-title":"Tamoxifen causes gene mutations in the livers of lambda\/lacI transgenic rats","volume":"57","author":"Davies","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib41","first-page":"53","article-title":"Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo","volume":"56","author":"Moorthy","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1021\/tx990144v","article-title":"4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides","volume":"13","author":"Fan","year":"2000","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib43","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1200\/JCO.1992.10.6.990","article-title":"Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors","volume":"10","author":"Wiebe","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib44","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/carcin\/18.11.2209","article-title":"Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen","volume":"18","author":"Martin","year":"1997","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jnci\/87.9.645","article-title":"Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group","volume":"87","author":"Rutqvist","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib46","first-page":"1475","article-title":"Lack of genotoxicity of tamoxifen in human endometrium","volume":"56","author":"Carmichael","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib47","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/carcin\/17.5.1149","article-title":"Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients","volume":"17","author":"Phillips","year":"1996","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib48","first-page":"4374","article-title":"Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients","volume":"56","author":"Hemminki","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib49","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/carcin\/19.10.1709","article-title":"Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture","volume":"19","author":"Glatt","year":"1998","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib50","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/carcin\/21.10.1851","article-title":"Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts","volume":"21","author":"Boocock","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib51","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/carcin\/17.8.1687","article-title":"Effect of tamoxifen feeding on metabolic activation of tamoxifen by the liver of the rhesus monkey: does liver accumulation of inhibitory metabolites protect from tamoxifen-dependent genotoxicity and cancer?","volume":"17","author":"Comoglio","year":"1996","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib52","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jnci\/djg080","article-title":"Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo","volume":"95","author":"Liu","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib53","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/0024-3205(83)90323-5","article-title":"Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels","volume":"32","author":"Clemens","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3816\/CBC.2002.n.020","article-title":"The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial","volume":"3","author":"Vogel","year":"2002","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1749-6632.2001.tb04018.x","article-title":"Rationale and overview of the raloxifene use for the heart (RUTH) trial","volume":"949","author":"Mosca","year":"2001","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beem.2003.08.002","article-title":"The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer","volume":"18","author":"Howell","year":"2004","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib58","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/jm020450x","article-title":"Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents","volume":"46","author":"Jordan","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)37755-9","article-title":"LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo","volume":"287","author":"Sato","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib60","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1200\/JCO.2001.19.7.2002","article-title":"Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer","volume":"19","author":"Munster","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ijc.10302","article-title":"Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice","volume":"99","author":"Gutman","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib62","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1021\/jm00037a002","article-title":"3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats","volume":"37","author":"Willson","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib63","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0026-895X(24)12119-0","article-title":"Differential response of estrogen receptors alpha and beta to SP500263, a novel potent selective estrogen receptor modulator","volume":"61","author":"Brady","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib64","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1210\/endo.139.11.6307","article-title":"LY353381.HCl (arzoxifene): an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1\u201334)","volume":"139","author":"Sato","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib65","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1359\/jbmr.2002.17.12.2256","article-title":"Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats","volume":"17","author":"Ma","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib66","first-page":"8412","article-title":"Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer","volume":"61","author":"Suh","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0960-0760(00)00087-X","article-title":"Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat","volume":"74","author":"Martel","year":"2000","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib68","first-page":"1439","article-title":"Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models","volume":"63","author":"Brady","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib69","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00223-002-1029-2","article-title":"Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat","volume":"72","author":"Sutherland","year":"2003","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib70","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2796.1999.00545.x","article-title":"Oestrogen receptors\u2014an overview","volume":"246","author":"Enmark","year":"1999","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.critrevonc.2003.09.003","article-title":"The biological role of estrogen receptors alpha and beta in cancer","volume":"50","author":"Pearce","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib72","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/science.3283939","article-title":"The steroid and thyroid hormone receptor superfamily","volume":"240","author":"Evans","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib73","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev.bi.63.070194.002315","article-title":"Molecular mechanisms of action of steroid\/thyroid receptor superfamily members","volume":"63","author":"Tsai","year":"1994","journal-title":"Ann. Rev. Biochem."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib74","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0092-8674(93)90390-C","article-title":"The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements","volume":"75","author":"Schwabe","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib75","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the estrogen receptor","volume":"389","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib76","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1210\/endo.138.3.4979","article-title":"Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta","volume":"138","author":"Kuiper","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib77","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1210\/endo.140.12.7179","article-title":"The estrogen receptor \u03b2-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens","volume":"140","author":"Hall","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib78","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib79","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1073\/pnas.96.7.3999","article-title":"Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta","volume":"96","author":"Paige","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib80","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0969-2126(01)00568-8","article-title":"Structural insights into the mode of action of a pure antiestrogen","volume":"9","author":"Pike","year":"2001","journal-title":"Structure"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib81","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0955-0674(98)80015-X","article-title":"The nuclear receptor lidand-binding domain; structure and function","volume":"10","author":"Moras","year":"1998","journal-title":"Curr. Opin. Cell. Biol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib82","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0960-0760(96)00184-7","article-title":"Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor","volume":"60","author":"Levenson","year":"1997","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib83","doi-asserted-by":"crossref","first-page":"9189","DOI":"10.1074\/jbc.M108335200","article-title":"Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells","volume":"277","author":"Liu","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib84","first-page":"5097","article-title":"Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex by substituting glycine for aspartate at amino acid 351","volume":"60","author":"MacGregor-Shafer","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF00689682","article-title":"Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice","volume":"31","author":"Wolf","year":"1994","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib86","first-page":"S447","article-title":"Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response","volume":"9","author":"Schiff","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib87","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/bcr742","article-title":"Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy","volume":"6","author":"Shao","year":"2004","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib88","doi-asserted-by":"crossref","first-page":"36869","DOI":"10.1074\/jbc.R100029200","article-title":"The multifaceted mechanisms of estradiol and estrogen receptor signaling","volume":"276","author":"Hall","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib89","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib90","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/MCB.24.1.14-24.2004","article-title":"Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins","volume":"24","author":"Lonard","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib91","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.277.5331.1508","article-title":"Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites","volume":"277","author":"Paech","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib92","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1074\/jbc.275.8.5379","article-title":"Ligand-, cell-, and estrogen receptor subtype (alpha\/beta)-dependent activation at GC-rich (Sp1) promoter elements","volume":"275","author":"Saville","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib93","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0960-0760(03)00010-4","article-title":"17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context","volume":"84","author":"Castro-Rivera","year":"2003","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib94","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1038\/sj.onc.1203828","article-title":"Estrogen receptor beta acts as a dominant regulator of estrogen signaling","volume":"19","author":"Pettersson","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib95","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1210\/endo.140.12.7179","article-title":"The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens","volume":"40","author":"Hall","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib96","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0303-7207(98)00212-3","article-title":"Characterization of membrane estrogen binding proteins from rabbit uterus","volume":"147","author":"Monje","year":"1999","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib97","first-page":"116","article-title":"Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation","volume":"16","author":"Song","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib98","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/sj.onc.1206937","article-title":"Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling","volume":"22","author":"Clarke","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib99","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","article-title":"Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial","volume":"22","author":"Howell","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1677\/erc.0.0060271","article-title":"Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer","volume":"6","author":"Osborne","year":"1999","journal-title":"Endocrinol. Relat. Cancer"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib101","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1023\/A:1025467500433","article-title":"The biology of antihormone failure in breast cancer","volume":"80","author":"Nicholson","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib102","first-page":"S524","article-title":"Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer","volume":"9","author":"Johnston","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib103","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrc721","article-title":"Endocrine-responsive breast cancer and strategies for combating resistance","volume":"2","author":"Ali","year":"2002","journal-title":"Nat. Rev. Cancer."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib104","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jnci\/95.5.353","article-title":"Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2\/neu in tamoxifen resistance in breast cancer","volume":"95","author":"Osborne","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib105","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib106","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1038\/sj.onc.1206779","article-title":"Biologic and therapeutic role of HER2 in cancer","volume":"22","author":"Menard","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib107","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1023\/B:BREA.0000032919.83803.48","article-title":"Prognostic and predictive impact of the HER-2\/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer","volume":"86","author":"Muller","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib108","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1096\/fj.02-0096fje","article-title":"Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR","volume":"16","author":"Dittmar","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib109","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/sj.bjc.6600219","article-title":"Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells","volume":"86","author":"Huang","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01961241","article-title":"Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu","volume":"24","author":"Benz","year":"1993","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib111","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1093\/emboj\/18.12.3348","article-title":"The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing","volume":"18","author":"Waterman","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib112","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1126\/science.277.5328.965","article-title":"AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer","volume":"277","author":"Anzick","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib113","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0960-9776(03)00137-1","article-title":"Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer","volume":"12","author":"Osborne","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib114","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.seminoncol.2003.08.006","article-title":"Dysregulation of cellular signaling by HER2\/neu in breast cancer","volume":"30","author":"Zhou","year":"2003","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib115","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1074\/jbc.M010840200","article-title":"Phosphatidylinositol 3-kinase\/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance","volume":"276","author":"Campbell","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib116","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","article-title":"Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer","volume":"96","author":"Shou","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib117","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0960-9776(03)00149-8","article-title":"Changing role of the oestrogen receptor in the life and death of breast cancer cells","volume":"12","author":"Jordan","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib118","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/jnci\/djg079","article-title":"Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer","volume":"95","author":"Osipo","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib119","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/jnci\/93.22.1714","article-title":"Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol","volume":"93","author":"Song","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib120","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/sj.bjc.6601627","article-title":"Targeting oestrogen to kill the cancer but not the patient","volume":"90","author":"Lewis","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib121","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1010619225209","article-title":"High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy","volume":"67","author":"Lonning","year":"2001","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mrfmmm.2005.02.028_bib122","first-page":"2028","article-title":"Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice","volume":"6","author":"Yao","year":"2000","journal-title":"Clin. Cancer Res."}],"container-title":["Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027510705002770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027510705002770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T21:38:37Z","timestamp":1764711517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0027510705002770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":122,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0027510705002770"],"URL":"https:\/\/doi.org\/10.1016\/j.mrfmmm.2005.02.028","relation":{},"ISSN":["1386-1964"],"issn-type":[{"value":"1386-1964","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance","name":"articletitle","label":"Article Title"},{"value":"Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mrfmmm.2005.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}